Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells

Free Radical Biology and Medicine

Volumn 50, Issue 2, 2011, Pages 313-322

  Pettazzoni, Piergiorgio ^a,b   Pizzimenti, Stefania ^a   Toaldo, Cristina ^a   Sotomayor, Paula ^b   Tagliavacca, Luigina ^b   Liu, Song ^b   Wang, Dan ^b   Minelli, Rosalba ^b   Ellis, Leigh ^b   Atadja, Peter ^c   Ciamporcero, Eric ^a   Dianzani, Mario Umberto ^a   Barrera, Giuseppina ^a   Pili, Roberto ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Androgen receptor; DNA damage; Free radicals; HNE; Mitotic arrest; Panobinostat; Prostate cancer

Indexed keywords

4 HYDROXYNONENAL; ALPHA TUBULIN; ANDROGEN RECEPTOR; CYCLIN DEPENDENT KINASE; HISTONE H3; PANOBINOSTAT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DEPHOSPHORYLATION; DNA DAMAGE; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; LIPID PEROXIDATION; MITOSIS INHIBITION; PRIORITY JOURNAL; PROSTATE CANCER;

ACETYLATION; ALDEHYDES; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CYSTEINE PROTEINASE INHIBITORS; DNA DAMAGE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GLUTATHIONE; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; LIPID PEROXIDATION; MALE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TUMOR CELLS, CULTURED;

EID: 78651244903     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2010.11.011     Document Type: Article

References (45)

1. A. Jemal, R.C. Tiwari, T. Murray, A. Ghafoor, A. Samuels, E. Ward, E.J. Feuer, and M.J. Thun American Cancer Society cancer statistics CA Cancer J. Clin. 54 2004 8 29
2. A. Abbas, and S. Gupta The role of histone deacetylases in prostate cancer Epigenetics 3 2008 300 309
3. A.A. Lane, and B.A. Chabner Histone deacetylase inhibitors in cancer therapy J. Clin. Oncol. 27 2009 5459 5468
4. S. Minucci, and P.G. Pelicci Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer Nat. Rev. Cancer 6 2006 38 51
5. R.R. Rosato, J.A. Almenara, S.C. Maggio, S. Coe, P. Atadja, P. Dent, and S. Grant Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions Mol. Cancer Ther. 7 2008 3285 3297
6. L. Ellis, M. Bots, R.K. Lindemann, J.E. Bolden, A. Newbold, L.A. Cluse, C.L. Scott, A. Strasser, P. Atadja, S.W. Lowe, and R.W. Johnstone The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy Blood 114 2009 380 393
7. S.K. Kachhap, N. Rosmus, S.J. Collis, M.S. Kortenhorst, M.D. Wissing, M. Hedayati, S. Shabbeer, J. Mendonca, J. Deangelis, L. Marchionni, J. Lin, N. Höti, J.W. Nortier, T.L. DeWeese, H. Hammers, and M.A. Carducci Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor PLoS ONE 5 2010 e11208
8. L. Khandrika, B. Kumar, S. Koul, P. Maroni, and H.K. Koul Oxidative stress in prostate cancer Cancer Lett. 282 2009 125 136
9. B. Kumar, S. Koul, L. Khandrika, R.B. Meacham, and H.K. Koul Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype Cancer Res. 68 2008 1777 1785
10. A.M. Oltra, F. Carbonell, C. Tormos, A. Iradi, and G.T. Sáez Antioxidant enzyme activities and the production of MDA and 8-oxo-dG in chronic lymphocytic leukemia Free Radic. Biol. Med. 30 2001 1286 1292
11. G. Ray, S. Batra, N.K. Shukla, S. Deo, V. Raina, S. Ashok, and S.A. Husain Lipid peroxidation, free radical production and antioxidant status in breast cancer Breast Cancer Res. Treat. 59 2000 163 170
12. D. Trachootham, J. Alexandre, and P. Huang Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discovery 8 2009 579 591
13. F. Gentile, S. Pizzimenti, A. Arcaro, P. Pettazzoni, R. Minelli, D. D'Angelo, G. Mamone, P. Ferranti, C. Toaldo, G. Cetrangolo, S. Formisano, M.U. Dianzani, K. Uchida, C. Dianzani, and G. Barrera Exposure of HL-60 human leukaemic cells to 4-hydroxynonenal promotes the formation of adduct(s) with alpha-enolase devoid of plasminogen binding activity Biochem. J. 422 2009 285 294
14. H. Esterbauer, R.J. Schaur, and H. Zollner Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes Free Radic. Biol. Med. 11 1991 81 128
15. G. Barrera, S. Pizzimenti, and M.U. Dianzani Lipid peroxidation: control of cell proliferation, cell differentiation and cell death Mol. Aspects Med. 29 2008 1 8
16. S. Laurora, E. Tamagno, F. Briatore, P. Bardini, S. Pizzimenti, C. Toaldo, P. Reffo, P. Costelli, M.U. Dianzani, O. Danni, and G. Barrera 4-Hydroxynonenal modulation of p53 family gene expression in the SK-N-BE neuroblastoma cell line Free Radic. Biol. Med. 38 2005 215 225
17. S. Pizzimenti, E. Menegatti, D. Berardi, C. Toaldo, P. Pettazzoni, R. Minelli, B. Giglioni, A. Cerbone, M.U. Dianzani, C. Ferretti, and G. Barrera 4-Hydroxynonenal, a lipid peroxidation product of dietary polyunsaturated fatty acids, has anticarcinogenic properties in colon carcinoma cell lines through the inhibition of telomerase activity J. Nutr. Biochem. 21 2010 818 826
18. D. Sarkar HDAC inhibitors and ionizing radiation: combinatorial strategy to combat lung cancer Cancer Biol. Ther. 8 2009 832 834
19. D.Z. Qian, Y. Kato, S. Shabbeer, Y. Wei, H.M. Verheul, B. Salumbides, T. Sanni, P. Atadja, and R. Pili Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589 Clin. Cancer Res. 12 2006 634 642
20. G. Barrera, C. Di Mauro, R. Muraca, D. Ferrero, G. Cavalli, V.M. Fazio, L. Paradisi, and M.U. Dianzani Induction of differentiation in human HL-60 cells by 4-hydroxynonenal, a product of lipid peroxidation Exp. Cell Res. 197 1991 148 152
21. W. Krek, and E.A. Nigg Differential phosphorylation of vertebrate p34cdc2 kinase at the G1/S and G2/M transitions of the cell cycle: identification of major phosphorylation sites EMBO J. 10 1991 305 316
22. A. Xiao, H. Li, D. Shechter, S.H. Ahn, L.A. Fabrizio, H. Erdjument-Bromage, S. Ishibe-Murakami, B. Wang, P. Tempst, K. Hofmann, D.J. Patel, S.J. Elledge, and C.D. Allis WSTF regulates the H2A.X DNA damage response via a novel tyrosine kinase activity Nature 457 2009 57 62
23. I.V. Litvinov, L. Antony, S.L. Dalrymple, R. Becker, L. Cheng, and J.T. Isaacs PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor Prostate 66 2006 1329 1338
24. W. Xu, L. Ngo, G. Perez, M. Dokmanovic, and P.A. Marks Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor Proc. Natl Acad. Sci. USA 103 2006 15540 15545
25. E. Niki Lipid peroxidation: physiological levels and dual biological effects Free Radic. Biol. Med. 47 2009 469 484
26. H. Strohmaier, H. Hinghofer-Szalkay, and R.J. Schaur Detection of 4-hydroxynonenal (HNE) as a physiological component in human plasma J. Lipid Mediatiators Cell Signal. 11 1995 51 61
27. G. Barrera, S. Pizzimenti, and M.U. Dianzani 4-Hydroxynonenal and regulation of cell cycle: effects on the pRb/E2F pathway Free Radic. Biol. Med. 37 2004 597 606
28. G. Barrera, S. Pizzimenti, S. Laurora, F. Briatore, C. Toaldo, and M.U. Dianzani 4-Hydroxynonenal and cell cycle Biofactors 24 2005 151 157
29. P. Maiso, X. Carvajal-Vergara, E.M. Ocio, R. López-Pérez, G. Mateo, N. Gutiérrez, P. Atadja, A. Pandiella, and J.F. San Miguel The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance Cancer Res. 66 2006 5781 5789
30. M.B. Prystowsky, A. Adomako, R.V. Smith, N. Kawachi, W. McKimpson, P. Atadja, Q. Chen, N.F. Schlecht, J.L. Parish, G. Childs, and T.J. Belbin The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines J. Pathol. 218 2009 467 477
31. A. Lindqvist, V. Rodríguez-Bravo, and R.H. Medema The decision to enter mitosis: feedback and redundancy in the mitotic entry network J. Cell Biol. 185 2009 193 202
32. T. Lorca, C. Bernis, S. Vigneron, A. Burgess, E. Brioudes, J.C. Labbé, and A. Castro Constant regulation of both the MPF amplification loop and the Greatwall-PP2A pathway is required for metaphase II arrest and correct entry into the first embryonic cell cycle J. Cell Sci. 123 2010 2281 2291
33. B.A. Wolfe, and K.L. Gould Inactivating Cdc25, mitotic style Cell Cycle 3 2004 601 603
34. O. Timofeev, O. Cizmecioglu, F. Settele, T. Kempf, and I. Hoffmann Cdc25 phosphatases are required for timely assembly of CDK1-cyclin B at the G2/M transition J. Biol. Chem. 285 2010 16978 16990
35. A. Herman-Antosiewicz, and S.V. Singh Checkpoint kinase 1 regulates diallyl trisulfide-induced mitotic arrest in human prostate cancer cells J. Biol. Chem. 280 2005 28519 28528
36. T.M. Kadia, H. Yang, A. Ferrajoli, S. Maddipotti, C. Schroeder, T.L. Madden, J.L. Holleran, M.J. Egorin, F. Ravandi, D.A. Thomas, W. Newsome, B. Sanchez-Gonzalez, J.A. Zwiebel, I. Espinoza-Delgado, H.M. Kantarjian, and G. Garcia-Manero A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia Br. J. Haematol. 150 2010 72 82
37. I.A. Kim, J.H. Shin, I.H. Kim, J.H. Kim, J.S. Kim, H.G. Wu, E.K. Chie, S.W. Ha, C.I. Park, and G.D. Kao Histone deacetylase inhibitor-mediated radiosensitization of human cancer cells: class differences and the potential influence of p53 Clin. Cancer Res. 12 2006 940 949
38. J.C. Purrucker, A. Fricke, M.F. Ong, C. Rübe, C.E. Rübe, and U. Mahlknecht HDAC inhibition radiosensitizes human normal tissue cells and reduces DNA double-strand break repair capacity Oncol. Rep. 23 2010 263 269
39. R.R. Rosato, S.S. Kolla, S.K. Hock, J.A. Almenara, A. Patel, S. Amin, P. Atadja, P.B. Fisher, P. Dent, and S. Grant Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway J. Biol. Chem. 285 2010 10064 10077
40. O. Falletti, J. Cadet, A. Favier, and T. Douki Trapping of 4-hydroxynonenal by glutathione efficiently prevents formation of DNA adducts in human cells Free Radic. Biol. Med. 42 2007 1258 1269
41. C. Morrison, and C.L. Rieder Chromosome damage and progression into and through mitosis in vertebrates 3 2004 DNA Repair (Amsterdam) 1133 1139
42. C.Y. Ho, and H.Y. Li DNA damage during mitosis invokes a JNK-mediated stress response that leads to cell death J. Cell. Biochem. 110 2010 725 731
43. 2-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1 Cancer Res. 62 2002 5743 5748
44. J.H. Pinthus, I. Bryskin, J. Trachtenberg, J.P. Lu, G. Singh, E. Fridman, and B.C. Wilson Androgen induces adaptation to oxidative stress in prostate cancer: implications for treatment with radiation therapy Neoplasia 9 2007 68 80
45. X. Liu, A. Gomez-Pinillos, X. Liu, E.M. Johnson, and A.C. Ferrari Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels Prostate 70 2010 179 189